Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

Settlement agreement nears between Drake and DMACC over logo usage "Lawmakers twiddle their thumbs": Trump administration rants as Democrats stop crypto bill A Tesla worker knew his anti-Elon Musk ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

British drugmaker GSK told Manhattan prosecutors that a former employee told colleagues Pfizer held back positive results until after the 2020 election. But the former employee, who worked at both ...

The 10-second video shows the rapper playing with a football and an ending tag, “See you at the game,” with the Pfizer logo. Additional teasers will be posted Saturday and Sunday mornings ...

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Pfizer (NYSE: PFE) is scheduled to report its Q3 2024 results on Tuesday, October 29. We expect the company to post revenue of $15.1 billion and earnings of $0.63 on a per share and adjusted basis ...

Pfizer and BioNTech may have a strong pedigree in the mRNA vaccine game, but, when it comes to flu, they’ve run up against the same problem as their peers—neutralizing influenza strain B.

On Thursday, Pfizer announced plans to advance its weight-loss pill after "encouraging" results from an early-stage study. The pharmaceutical giant is trying to tap into the highly lucrative ...